Bendamustine hydrochloride - CAS 3543-75-7
Catalog number: 3543-75-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H21Cl2N3O2.HCl
Molecular Weight:
394.72
COA:
Inquire
Targets:
Others
Description:
Bendamustine hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown, this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
SDX-105 (Cytostasane) HCl
MSDS:
Inquire
1.Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Laurenti L1, Innocenti I2, Autore F2, Vannata B3, Efremov DG4, Ciolli S5, Del Poeta G6, Mauro FR7, Cortelezzi A8, Borza PA9, Ghio F10, Mondello P11, Murru R12, Gozzetti A13, Cariccio MR14, Piccirillo N2, Boncompagni R5, Cantonetti M6, Principe MI6, Reda G Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.
The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly patients. German CLL study group compared FCR vs. bendamustine-rituximab (BR) in fit untreated patients. The response rates with BR or FCR were comparable, BR could be an alternative 1st-line treatment for elderly patients. Here we report retrospective data of 70 elderly (≥65 years) CLL patients from 12 Italian centers treated with BR as front-line therapy. The primary end points were overall response rate (complete remission/partial remission) and safety. Forty-seven males and 23 females, with a median age of 72 years, were included in the study. Eight patients were unfit for CIRS. The OR rate was 88.6% (31.4% CR and 57.2% PR). Progression free survival, treatment free survival and overall survival rates at 2-years were 79%, 90.
2.Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ1, Bordoni RE2, Grant SC3, Saleh MN4, Reddy VB5, Jerome ML6, Dixon PM7, Miley DK6, Singh KP8, Robert F9. Cancer Chemother Pharmacol. 2015 Nov;76(5):949-55. doi: 10.1007/s00280-015-2869-6. Epub 2015 Sep 22.
PURPOSE: The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastrophe. Absent expression of ERCC-1 and expression of topoisomerases were hypothesized to be predictive for PFS and OS.
3.Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS1, Goy A2, Lamonica D3, Graf DA3,4, Munteanu MC5, van der Jagt RH6. Ann Hematol. 2015 Dec;94(12):2025-32. doi: 10.1007/s00277-015-2478-9. Epub 2015 Sep 28.
In most cases of relapsed/refractory mantle cell lymphoma (MCL), patients respond to salvage therapy, though typically responses are partial and/or transient followed by disease progression, even with newer agents (e.g., ibrutinib). In this multicenter, open-label, single-arm, phase II study, patients with relapsed/refractory non-blastoid MCL received bendamustine 90 mg/m(2) (days 1 and 2) and rituximab 375 mg/m(2) (day 1) for 6 planned 28-day cycles. Functional imaging with 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) was conducted at baseline and after cycle 6. Forty-five patients were enrolled (median age, 70 years; 82 % stage IV disease; median number of prior chemotherapies, 2 [range, 1-4]), showing an overall response rate (ORR; primary efficacy measure) of 82 % (complete response [CR], 40 %; partial response, 42 %). In the 32 patients with complete 18F-FDG PET/CT data, 75 % achieved a complete metabolic response.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


MI-463
(CAS: 1628317-18-9)

MI-463, a thienopyrimidine derivative, has been found to be a menin inhibitor that could be significant in Leukaemia studies.

CAS 118525-36-3 Sagittatoside B

Sagittatoside B
(CAS: 118525-36-3)

Sagittatoside B is a natural compound isolated from traditional Chinese herb Yinyanghuo (Herba Epimdii).

AM-643
(CAS: 1233114-22-1)

AM-643 is an active molecular. In the Biological Tests, it can inhibit FLAP in human whole blood assessed as inhibition of calcium ionophore A23187-induced LTB...

CAS 1227633-49-9 SR-1

SR-1
(CAS: 1227633-49-9)

CAS 1465248-60-5 SPL-B

SPL-B
(CAS: 1465248-60-5)

SPL-B is an orally active inhibitor of transforming acidic coiled-coil protein (TACC3) exhibiting an inhibitory effect against the nucleation of centrosome micr...

CAS 4382-63-2 PFK15

PFK15
(CAS: 4382-63-2)

PFK15 is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) with IC50 of 207 nM.

AMZ30
(CAS: 1313613-09-0)

AMZ30, a PME-1 inhibitor, could inhibit PME-1 irreversiblely and be significant in the pharmacological study of determinating the demethylated PP2A function. IC...

CAS 35189-28-7 Norgestimate

Norgestimate
(CAS: 35189-28-7)

Norgestimate is a form of progesterone used with estradiol to treat the symptoms of menopause.

SBC-115076
(CAS: 489415-96-5)

SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist. .

CAS 127654-03-9 KF 13218

KF 13218
(CAS: 127654-03-9)

KF 13218, a novel pyridobenzazepinone derivative, inhibited human and bovine platelet thromboxane synthase with IC50 values of 27 +/- 5.8 nmol/l (mean +/- S.E.M...

CAS 41498-37-7 GS 389

GS 389
(CAS: 41498-37-7)

GS 389 is a novel tetrahydroisoquinoline analog which significantly increased cGMP levels in the rat aorta and inhibited cGMP phosphodiesterase from the rabbit ...

CAS 53-84-9 NAD+

NAD+
(CAS: 53-84-9)

NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It plays a role in the activity of...

CEF4

CEF4 is a peptide that corresponds to aa 342-351 of the influenza A virus nucleocapsid protein. CEF peptides are v-Src-induced cytokines from chicken embryo fib...

CAS 371980-98-2 SB 612111 hydrochloride

SB 612111 hydrochloride
(CAS: 371980-98-2)

SB 612111 hydrochloride is a selective nociceptin/orphanin FQ (NOP) receptor antagonist (Ki value 0.33, 57.6, 160.5 and 2109 nM for NOP, μ-, κ- and δ-receptors ...

CAS 1798328-24-1 TD52

TD52
(CAS: 1798328-24-1)

TD52 is a potent CIP2A inhibitor with increased apoptosis in HCC cells compared to erlotinib (IC50 values of 0.9, 0.9, 0.8 and 1.2 μM in HA22T, Hep3B, PLC5 and ...

CAS 1140525-25-2 SB290157 trifluoroacetate

SB290157 trifluoroacetate
(CAS: 1140525-25-2)

SB290157 trifluoroacetate is selective, high affinity, competitive C3areceptor antagonist (IC50= 200 nM) suitable for use in animal models of inflammation.

ABT116
(CAS: 1008529-42-7)

ABT116 is an antagonist of transient receptor potential vanilloid type 1.

CAS 55297-96-6 Tiamulin Fumarate

Tiamulin Fumarate
(CAS: 55297-96-6)

Tiamulin Fumarate is a derivative of Pleuromutilin, acts as an antibacterial.

AM-2159
(CAS: 83654-06-2)

AM-2159 is a bio-active chemical, but no detailed information has been published yet.

CAS 1228280-29-2 KY 05009

KY 05009
(CAS: 1228280-29-2)

KY 05009 is an inhibitor of Traf2- and Nck-Interacting Kinase (TNIK; Ki value 100 nM in ATP competitive assay) that attenuates TGF-β1-mediated Wnt and Smad sign...

Chemical Structure

CAS 3543-75-7 Bendamustine hydrochloride

Quick Inquiry

Verification code

Featured Items